Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...
DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.
C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...
While Health Technology Assessment agencies anticipate that joint efforts and harmonisation will enhance evaluations’ ...
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell and gene therapies and help ensure consistent safety and efficacy ...
Russian attackers were behind the hack of the European Medicines Agency EMA in 2020. They had “unauthorized access to ...
The European Medicines Agency has started a review of medicines containing finasteride and dutasteride following concerns ...
Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and Apellis has exclusive U.S.
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...